Physician profile
Aaron Wever
NPI 1104873959
$4,228.87
in general payments reported to CMS, 2019-2025
23 companies · $1,669 in 2025
The $1,669 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $44.97 · 2021: $102 · 2022: $317 · 2023: $339 · 2024: $1,504 · 2025: $1,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,272 · Education: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,271.70 |
| Education | $239.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $809.47 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $486.47 | 2019-2025 | Tremfya |
| Ucb, INC. | $417.68 | 2019-2025 | Bimzelx |
| Lilly USA, LLC | $358.96 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $351.25 | 2019-2025 | |
| Genzyme Corporation | $260.69 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $244.44 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $176.10 | 2024-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $171.25 | 2023-2025 | Sotyktu |
| Leo Pharma INC. | $146.27 | 2023-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $139.67 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $133.75 | 2019-2025 | |
| Pfizer INC. | $98.85 | 2024-2025 | |
| Galderma Laboratories, L.P. | $96.27 | 2024-2025 | Nemluvio |
| Almirall LLC | $50.63 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $48.57 | 2025 | Otezla |
| Botanix Sb INC | $40.04 | 2025 | Sofdra |
| Incyte Corporation | $39.63 | 2021-2024 | Opzelura |
| Organon LLC | $38.55 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $38.23 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $36.99 | 2025 | Dupixent |
| Journey Medical Corporation | $25.33 | 2025 | |
| Celgene Corporation | $19.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Wever listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.